论文部分内容阅读
目的:验证SF-36量表在中国人群中的有效性,及其在抗结核治疗中病人健康相关生命质量(HQoL)评估中的应用。设计:用SF-36量表(中文版)对102名结核病人在治疗前、治疗初期和治疗末的调查得分与103名对照人群进行比较。结果:SF-36量表的准确性(内部一致性>0.4)和可靠性(克朗巴赫系数α>0.7)均较好。除情感角色、社会功能和心理健康外,疗前结核病人的得分都低于对照组(P<0.01);治疗中病人的得分显著升高(P<0.01)。逐步回归模型分析结果显示,年龄(P<0.01,OR=0.95)、白细胞数(P<0.01,OR=0.92)和症状数(P<0.05,OR=0.99)与SF-36量表总得分相关。在完成疗程的病人中,性别(P<0.01,OR=0.25)和血红蛋白(P<0.05,OR=0.88)为模型中与总得分有关的因素。结论:结核病人治疗前SF-36量表得分低,表明健康相关生命质量(HqoL)下降,躯体健康得分影响最大。量表得分随疗程增加。中文版SF-36量表是抗结核治疗过程中监测病人HQoL的可靠工具。
PURPOSE: To verify the effectiveness of the SF-36 scale in Chinese population and its application in assessing patients’ health-related quality of life (HQoL) in anti-TB treatment. Design: The survey scores of 102 TB patients before treatment, initial treatment and end of treatment were compared with 103 control subjects using the SF-36 Scale (Chinese version). Results: The SF-36 scale accuracy (internal consistency> 0.4) and reliability (Cronbach’s coefficient α> 0.7) were good. Except for emotional role, social function and mental health, scores of pretreatment TB patients were lower than those of the control group (P <0.01). Patients’ scores during treatment were significantly higher (P <0.01). Stepwise regression analysis showed that age (P <0.01, OR = 0.95), leukocyte count (P <0.01, OR = 0.92) and symptom number (P <0.05, OR = 0.99) were correlated with the total score of SF-36 . Among the patients who completed the treatment, gender (P <0.01, OR = 0.25) and hemoglobin (P <0.05, OR = 0.88) were the factors associated with the total score in the model. Conclusion: The low score of SF-36 before TB treatment showed that the health-related quality of life (HqoL) decreased and the physical health score had the greatest impact. Scores increased with course of treatment. The Chinese version of SF-36 is a reliable tool for monitoring patients with HQoL during anti-TB treatment.